169 related articles for article (PubMed ID: 18626731)
1. Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase.
Kami J; Muranaka K; Yanagi Y; Obata R; Tamaki Y; Shibuya M
Jpn J Ophthalmol; 2008; 52(2):91-98. PubMed ID: 18626731
[TBL] [Abstract][Full Text] [Related]
2. Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor.
Takeda A; Hata Y; Shiose S; Sassa Y; Honda M; Fujisawa K; Sakamoto T; Ishibashi T
Graefes Arch Clin Exp Ophthalmol; 2003 Sep; 241(9):765-72. PubMed ID: 12937991
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.
Itokawa T; Nokihara H; Nishioka Y; Sone S; Iwamoto Y; Yamada Y; Cherrington J; McMahon G; Shibuya M; Kuwano M; Ono M
Mol Cancer Ther; 2002 Mar; 1(5):295-302. PubMed ID: 12489845
[TBL] [Abstract][Full Text] [Related]
5. Suppression of choroidal neovascularization by vasohibin-1, a vascular endothelium-derived angiogenic inhibitor.
Wakusawa R; Abe T; Sato H; Sonoda H; Sato M; Mitsuda Y; Takakura T; Fukushima T; Onami H; Nagai N; Ishikawa Y; Nishida K; Sato Y
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3272-80. PubMed ID: 21345982
[TBL] [Abstract][Full Text] [Related]
6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo.
Takahashi H; Tamaki Y; Ishii N; Oikawa N; Mizuguchi E; Francis JH; Inoue Y; Iriyama A; Obata R; Yanagi Y
Curr Eye Res; 2008 Nov; 33(11):1002-10. PubMed ID: 19085383
[TBL] [Abstract][Full Text] [Related]
8. A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo.
Takahashi H; Obata R; Tamaki Y
J Ocul Pharmacol Ther; 2006 Aug; 22(4):213-8. PubMed ID: 16910860
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization.
Keskin U; Totan Y; Karadağ R; Erdurmuş M; Aydın B
Ophthalmic Res; 2012; 47(1):13-8. PubMed ID: 21691137
[TBL] [Abstract][Full Text] [Related]
10. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
Kim KL; Suh W
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
[TBL] [Abstract][Full Text] [Related]
11. The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation.
Roberts DM; Kearney JB; Johnson JH; Rosenberg MP; Kumar R; Bautch VL
Am J Pathol; 2004 May; 164(5):1531-5. PubMed ID: 15111299
[TBL] [Abstract][Full Text] [Related]
12. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.
Kinose F; Roscilli G; Lamartina S; Anderson KD; Bonelli F; Spence SG; Ciliberto G; Vogt TF; Holder DJ; Toniatti C; Thut CJ
Mol Vis; 2005 May; 11():366-73. PubMed ID: 15951738
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
Roman CD; Choy H; Nanney L; Riordan C; Parman K; Johnson D; Beauchamp RD
J Surg Res; 2002 Jun; 105(1):43-7. PubMed ID: 12069500
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human VEGF165b inhibits experimental choroidal neovascularization.
Hua J; Spee C; Kase S; Rennel ES; Magnussen AL; Qiu Y; Varey A; Dhayade S; Churchill AJ; Harper SJ; Bates DO; Hinton DR
Invest Ophthalmol Vis Sci; 2010 Aug; 51(8):4282-8. PubMed ID: 20237252
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
Seo S; Suh W
Mol Vis; 2017; 23():823-831. PubMed ID: 29225458
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.
Shaheen RM; Davis DW; Liu W; Zebrowski BK; Wilson MR; Bucana CD; McConkey DJ; McMahon G; Ellis LM
Cancer Res; 1999 Nov; 59(21):5412-6. PubMed ID: 10554007
[TBL] [Abstract][Full Text] [Related]
18. Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse.
Heryanto B; Lipson KE; Rogers PA
Reproduction; 2003 Mar; 125(3):337-46. PubMed ID: 12611597
[TBL] [Abstract][Full Text] [Related]
19. Laser-induced choroidal neovascularization in mice attenuated by deficiency in the apelin-APJ system.
Hara C; Kasai A; Gomi F; Satooka T; Sakimoto S; Nakai K; Yoshioka Y; Yamamuro A; Maeda S; Nishida K
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):4321-9. PubMed ID: 23722395
[TBL] [Abstract][Full Text] [Related]
20. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G
Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
